This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
USNA vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
USANA Health (USNA) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
USANA Health (USNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Explore 5 Top-Ranked Stocks Using the DuPont Analysis
by Sanghamitra Saha
Have more faith in DuPont analysis than simple ROE calculation? Bet on these five stocks.
USNA or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
Esperion (ESPR) Q4 Earnings Miss, Coronavirus Woes Continue
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports dismal fourth-quarter results as it misses estimates for earnings and sales. Sales were hurt due to COVID-19.
Jazz Pharma (JAZZ) Q4 Earnings Miss, 2021 Sales View Dull
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports mixed fourth-quarter 2020 results as earnings miss estimates while sales beat the same. Shares down.
5 Low Price-to-Book Stocks for Value Investors
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics
Moving Average Crossover Alert: USANA Health Sciences (USNA)
by Zacks Equity Research
USANA Health Sciences (USNA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty
by Kinjel Shah
Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry in 2021. However, with demand trends expected to improve, USNA, RDUS, ONCT, ORGO and TPTX may prove to be good additions to one's portfolio.
USNA vs. CTLT: Which Stock Is the Better Value Option?
by Zacks Equity Research
USNA vs. CTLT: Which Stock Is the Better Value Option?
USANA Health Sciences (USNA) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of 34.53% and 8.31%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate USANA Health Sciences (USNA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
USANA Health (USNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Pick USANA Health (USNA) Stock Now?
by Zacks Equity Research
Is USANA Health Sciences (USNA) a great pick from the value investor's perspective right now? Read on to know more.
Jazz Pharma (JAZZ) Beats on Q3 Earnings, Ups Sales Guidance
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports better-than-expected third-quarter 2020 earnings and revenues and ups its sales guidance for 2020.
Is USANA Health Sciences (USNA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (USNA) Outperforming Other Medical Stocks This Year?
USANA Health Sciences (USNA) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of 11.63% and 5.93%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
USANA Health Sciences (USNA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
USANA Health (USNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 DuPont-Rich Quality Picks to Handle Sudden Sell-Off
by Sanghamitra Saha
Why you should depend on the DuPont technique to pick solid profit-generating stocks.
Zacks.com featured highlights include: MED, SYX, USNA, HUM and XPEL
by Zacks Equity Research
Zacks.com featured highlights include: MED, SYX, USNA, HUM and XPEL
Play DuPont Technique to Bet on 5 Top-Ranked Stocks
by Sanghamitra Saha
Have more faith in DuPont analysis than simple ROE calculation? Bet on these five stocks.
Has USANA Health Sciences (USNA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (USNA) Outperforming Other Medical Stocks This Year?
Zacks.com featured highlights include: Medifast, USANA Health, UFP Industries, AllianceBernstein and Landstar System
by Zacks Equity Research
Zacks.com featured highlights include: Medifast, USANA Health, UFP Industries, AllianceBernstein and Landstar System
6 Must-Buy Quality Stocks Screened on DuPont Analysis
by Sanghamitra Saha
Bet on six top-ranked stocks with higher ROE derived the DuPont way.
Has USANA Health Sciences (USNA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (USNA) Outperforming Other Medical Stocks This Year?